Agmatine Induces Rat Prostate Relaxation through Activation of Peripheral Imidazoline I2 -Receptors. 2013

Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
Department of Urology, College of Medicine, Taipei Medical University, Wan-Fang Hospital, Taipei, TaiwanDepartment of Surgery, Chi-Mei Medical Center Liouying, Tainan, TaiwanDepartment of Urology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, TaiwanDepartment of Medical Research, Chi-Mei Medical Center, Tainan, TaiwanDepartment of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

OBJECTIVE The effect of agmatine on prostate contractility as well as the roles of imidazoline receptors and potassium channels in this action were studied using isolated Wistar rat prostate tissue. METHODS Rat prostate strips were pre-contracted with 1 µmol/L phenylephrine or 50 mmol/L KCl. The relaxation response to agmatine (1-100 µmol/L) was measured. The effects of imidazoline receptor blockers: efaroxan, BU224, KU14R; ATP-sensitive K(+) channels (KATP ) channel inhibitor: glibenclamide; cyclic AMP (cAMP) phosphodiesterase inhibitor: IBMX; or protein kinase A (PKA) inhibitor: H-89 on the agmatine-induced relaxation were studied. RESULTS Agmatine produced relaxation in prostate strips pre-contracted with phenylephrine or KCl in a dose-dependent manner. This relaxation was significantly reduced by BU224, a selective I2 imidazoline receptor (IR) blocker, but not by I1 or I3 IR blockers (efaroxan, KU14R respectively). Moreover, the agmatine-induced relaxation was attenuated by glibenclamide and H-89, but enhanced by IBMX. CONCLUSIONS The results suggest that agmatine causes rat prostate relaxation by activation of the I2 IR, which opens KATP channels through cAMP/PKA pathway.

UI MeSH Term Description Entries

Related Publications

Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
July 2009, Neuroscience letters,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
May 2014, Lower urinary tract symptoms,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
March 2011, Neurourology and urodynamics,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
August 2016, Biochemical and biophysical research communications,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
April 2019, Alcoholism, clinical and experimental research,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
October 2017, Pharmacology & therapeutics,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
July 1995, Annals of the New York Academy of Sciences,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
January 2003, Eksperimental'naia i klinicheskaia farmakologiia,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
January 1997, Polish journal of pharmacology,
Liang-Ming Lee, and Chia-Ho Lin, and Hsien-Hui Chung, and Juei-Tang Cheng, and I-Hung Chen, and Yat-Ching Tong
May 2011, European journal of pharmacology,
Copied contents to your clipboard!